-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chikungunya virus (CHIKV) first appeared in Tanzania in 1951, and then reappeared in a series of outbreaks in Kenya, the Indian Ocean (2004-2006) and the Americas (2013-2017)
.
Chikungunya virus has become a major international health problem with acute and long-term effects on public health
CHIKV is an RNA alpha virus of the Togaviridae family, which is transmitted to humans by Aedes aegypti and Aedes albopictus in urban environments
.
These two kinds of mosquitoes have spread to all continents.
The main concern for CHIKV infection is the persistent and disabling polyarthralgia of the infected person
.
Recently, researchers published an article in Nature Communications to introduce the results of the first human trial of the candidate mimic adenovirus vector vaccine ChAdOx1 Chik
The results of the first human trial of ChAdOx1 Chik infection The results of the first human trial of ChAdOx1 Chik
In a dose-escalation, open-label, non-randomized and non-controlled phase 1 trial, the researchers recruited 24 healthy adult volunteers aged 18-50 (registration number NCT03590392)
.
Participants received a single intramuscular injection of ChAdOx1 Chik at one of three predetermined doses and were followed up for 6 months
immunity
T cell response rate over time
T cell response rate change with time T cell response rate change with timeThe results showed that ChAdOx1 Chik was safe at all doses tested , and there were no reports of serious adverse reactions
.
The vast majority of adverse events are mild or moderate, and self-limiting
ChAdOx1 Chik is safe at all doses tested ChAdOx1 Chik is safe at all doses tested
In addition, a single dose of the vaccine can induce IgG and T cell responses to CHIKV structural antigens
.
Broadly neutralizing antibodies against the four lines of CHIKV were found in all participants , and this antibody was discovered 2 weeks after vaccination
A single dose of vaccine can induce IgG and T cell responses against CHIKV structural antigens.
Original source:
Original source:Pedro M.
Pedro M.
Leave a message here
